These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 22999414)

  • 1. The effects of warfarin and edoxaban, an oral direct factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-osteocalcin) in rats.
    Morishima Y; Kamisato C; Honda Y; Furugohri T; Shibano T
    Thromb Res; 2013 Jan; 131(1):59-63. PubMed ID: 22999414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
    Morishima Y; Honda Y; Kamisato C; Tsuji N; Kita A; Edo N; Shibano T
    Thromb Res; 2012 Sep; 130(3):514-9. PubMed ID: 22647432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
    Shirasaki Y; Morishima Y; Shibano T
    Thromb Res; 2014 Apr; 133(4):622-8. PubMed ID: 23932349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
    Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
    Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Edoxaban: a new oral direct factor xa inhibitor.
    Camm AJ; Bounameaux H
    Drugs; 2011 Aug; 71(12):1503-26. PubMed ID: 21861537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.
    Mendell J; Noveck RJ; Shi M
    Br J Clin Pharmacol; 2013 Apr; 75(4):966-78. PubMed ID: 22924409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diet- or warfarin-induced vitamin K insufficiency elevates circulating undercarboxylated osteocalcin without altering skeletal status in growing female rats.
    Haffa A; Krueger D; Bruner J; Engelke J; Gundberg C; Akhter M; Binkley N
    J Bone Miner Res; 2000 May; 15(5):872-8. PubMed ID: 10804016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
    Piazza G; Mani V; Goldhaber SZ; Grosso MA; Mercuri M; Lanz HJ; Schussler S; Hsu C; Chinigo A; Ritchie B; Nadar V; Cannon K; Pullman J; Concha M; Schul M; Fayad ZA;
    Vasc Med; 2016 Aug; 21(4):361-8. PubMed ID: 27165711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
    Di Nisio M; Raskob G; Büller HR; Grosso MA; Zhang G; Winters SM; Cohen A
    Thromb Haemost; 2017 Apr; 117(4):784-793. PubMed ID: 28151543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
    Fukuda T; Honda Y; Kamisato C; Morishima Y; Shibano T
    Thromb Haemost; 2012 Feb; 107(2):253-9. PubMed ID: 22186946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin.
    Yamaji H; Murakami T; Hina K; Higashiya S; Kawamura H; Murakami M; Kamikawa S; Hirohata S; Kusachi S
    J Cardiovasc Electrophysiol; 2018 Jun; 29(6):835-843. PubMed ID: 29533476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
    Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
    Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.
    Fukuda T; Tsuji N; Honda Y; Kamisato C; Morishima Y; Shibano T
    Thromb Haemost; 2011 Dec; 106(6):1062-8. PubMed ID: 21946952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
    Morishima Y; Kamisato C; Honda Y
    Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
    Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
    Hillarp A; Strandberg K; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Lindahl TL
    Scand J Clin Lab Invest; 2018; 78(7-8):575-583. PubMed ID: 30278787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents.
    Honda Y; Kamisato C; Morishima Y
    Eur J Pharmacol; 2016 Sep; 786():246-252. PubMed ID: 27288116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edoxaban: a focused review of its clinical pharmacology.
    Lip GY; Agnelli G
    Eur Heart J; 2014 Jul; 35(28):1844-55. PubMed ID: 24810388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.